# Administrative supplement for Early Drug Development Opportunity Program (EDDOP)

> **NIH NIH P30** · DARTMOUTH COLLEGE · 2022 · $75,000

## Abstract

ABSTRACT
This proposal addresses Dartmouth Cancer Center’s (DCC) ability to conduct and participate in
cancer early phase clinical trials through the Experimental Therapeutics Clinical Trials Network
(ETCTN) of the National Cancer Institute (NCI). It serves as a comprehensive response to the
NCI’s P30 Cancer Center Support Grant Administrative Supplement, to NCI-designated Cancer
Centers previously participating in Create Access to Targeted Cancer Therapy for Underserved
Populations (CATCH-UP), to promote continued collaboration with CTEP’s ETCTN under
funding opportunity PA-20-272. DCC’s objectives as an NCI-designated comprehensive cancer
center are aligned with ETCTN’s goals to conduct early phase clinical treatment trials across a
broad range of cancers and diverse patient populations, with an emphasis on rare diseases.
DCC was approved through peer review for the NCI Cancer Center’s Early Phase Clinical
Research component of NCI Center Grants. Dartmouth is a Lead Academic Participating Site
in the NCI National Clinical Trials Network. We currently are not affiliated with any ETCTN UM1
grantees that are funded to conduct studies of NCI-IND agents with a phase 1, and more
recently also with phase 2, emphasis. Our proposal utilizes a pre-existing and functioning
cadre of established inter- and multidisciplinary investigators at DCC, The Geisel School of
Medicine at Dartmouth (Geisel), Dartmouth Health (DH), and the Thayer School of Engineering
at Dartmouth, which share common clinical, basic science and clinical translational research
interests in cancer treatment and imaging. We have core laboratories and an infrastructure that
supports the conduct of a wide spectrum of correlative science studies typically associated with
early phase trials and basic research in cancer biology, immunology, and imaging. As an
academic NCI-designated comprehensive cancer center, we are well-positioned to provide
scientific leadership in developing and conducting innovative early phase studies of anti-cancer
agents held under CTEP’s IND, as well as substantial numbers of patients eligible for accrual to
clinical trials conducted across the entire ETCTN.

## Key facts

- **NIH application ID:** 10677500
- **Project number:** 3P30CA023108-43S2
- **Recipient organization:** DARTMOUTH COLLEGE
- **Principal Investigator:** Steven D Leach
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $75,000
- **Award type:** 3
- **Project period:** 2022-09-01 → 2024-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10677500

## Citation

> US National Institutes of Health, RePORTER application 10677500, Administrative supplement for Early Drug Development Opportunity Program (EDDOP) (3P30CA023108-43S2). Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/grant/nih/10677500. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*